查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1703455

头孢氨芐市场－全球产业规模、份额、趋势、机会和预测，按销售通路、最终用途、地区和竞争细分，2020-2030 年

Cephalexin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球头孢氨芐市场价值为 3.7514 亿美元，预计到 2030 年将达到 4.5811 亿美元，预测期内年复合成长率(CAGR) 为 4.01%。这种稳定的成长轨迹主要受到对有效且具成本效益的抗生素治疗的需求不断增长的推动。

市场概览
预测期 2026-2030
2024年市场规模 3.7514亿美元
2030年市场规模 4.5811亿美元
2025-2030 年复合年增长率 4.01%
成长最快的领域 直接的
最大的市场 亚太

头孢氨芐是第一代头孢菌素，广泛用于治疗多种细菌感染，包括影响呼吸道、皮肤、泌尿道和骨骼的感染。它对革兰氏阳性菌具有广谱功效，加上强大的安全性和可承受性，使其成为已开发和新兴医疗保健市场的首选抗生素。

推动市场扩张的关键因素是细菌感染发生率的不断上升，尤其是在老龄化人口、免疫系统受损的个体以及接受手术后需要抗生素预防的患者中。由于头孢氨芐作为一线治疗药物具有公认的临床可靠性和有效性，因此它继续成为医疗保健专业人士值得信赖的选择。

然而，市场面临着日益严重的抗菌素抗药性挑战以及来自活性范围更广的新一代抗生素的竞争。儘管面临这些挑战，头孢氨芐仍然适用于治疗非抗药性感染，并在多个治疗领域的临床指南中占有一席之地。

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

适应症和治疗范围有限

主要市场趋势

细菌感染盛行率不断上升

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球头孢氨芐市场的影响

第五章：全球头孢氨芐市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按销售管道（直接、间接）
    • 依最终用途（泌尿道感染、呼吸道感染、中耳炎、骨骼感染、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美头孢氨芐市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲头孢氨芐市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太头孢氨芐市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲头孢氨芐市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东与非洲头孢氨芐市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第 13 章：全球头孢氨芐市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • Aurobindo Pharma Limited
  • Lupin Limited
  • Dykes & Dunes Enterprises Pvt. Ltd
  • Excel Pharma Chem
  • Zhejiang Anglikang Pharmaceutical Co., Ltd.,
  • Centrient Pharmaceuticals (Zibo) Co., Ltd
  • Hubei widely chemical technology Co., Ltd
  • Zhejiang Zhebang Pharmaceutical Co., Ltd
  • Akums Drugs and Pharmaceuticals Ltd.
  • Xi'an Harmonious Natural Biotechnology Co., Ltd

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 28249

Global Cephalexin market was valued at USD 375.14 million in 2024 and is projected to reach USD 458.11 million by 2030, expanding at a compound annual growth rate (CAGR) of 4.01% during the forecast period. This steady growth trajectory is primarily driven by rising demand for effective and cost-efficient antibiotic treatments.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 375.14 Million
Market Size 2030USD 458.11 Million
CAGR 2025-20304.01%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

Cephalexin, a first-generation cephalosporin, is widely prescribed for the treatment of a broad range of bacterial infections, including those affecting the respiratory tract, skin, urinary tract, and bones. Its broad-spectrum efficacy against Gram-positive bacteria, coupled with a strong safety profile and affordability, has positioned it as a preferred antibiotic in both developed and emerging healthcare markets.

A key factor contributing to market expansion is the increasing incidence of bacterial infections, particularly among aging populations, individuals with compromised immune systems, and patients undergoing surgical procedures that require post-operative antibiotic prophylaxis. Due to its established clinical reliability and effectiveness as a first-line treatment, cephalexin continues to be a trusted choice among healthcare professionals.

However, the market faces headwinds from the growing challenge of antimicrobial resistance and competition from newer-generation antibiotics with broader spectrums of activity. Despite these challenges, cephalexin remains relevant for the treatment of non-resistant infections and maintains its presence in clinical guidelines across multiple therapeutic areas.

Key Market Drivers

Growth of the Healthcare Industry

The expansion of the global healthcare sector serves as a significant catalyst for the cephalexin market. The hospital segment, in particular, is witnessing robust growth. In 2022, hospitals accounted for approximately 40% of the global healthcare market, valued at over USD 3.9 trillion. By 2029, this share is expected to increase to 44%, reaching a market size of USD 5.19 trillion.

As hospitals continue to play a central role in healthcare delivery-fueled by increasing demand and a growing global population-the need for reliable, first-line antibiotics such as cephalexin is expected to rise. Cephalexin's versatility in treating common infections such as respiratory, skin, and urinary tract infections makes it an essential component of both inpatient and outpatient care protocols.

Key Market Challenges

Limited Indications and Therapeutic Range

One of the primary limitations affecting the growth potential of the cephalexin market is its relatively narrow therapeutic scope. As a first-generation cephalosporin, cephalexin demonstrates high efficacy predominantly against Gram-positive bacterial strains, which restricts its use in treating more complex or drug-resistant infections.

Its clinical applications are generally confined to mild-to-moderate conditions such as respiratory, skin, urinary tract, and certain dental infections. Consequently, healthcare providers frequently opt for broader-spectrum or more potent alternatives-such as third- and fourth-generation cephalosporins, fluoroquinolones, or combination therapies-particularly in severe or hospital-acquired infections. This limits cephalexin's utility in high-acuity and specialized care settings, constraining its adoption in advanced clinical environments.

Key Market Trends

Increasing Prevalence of Bacterial Infections

The growing global burden of bacterial infections is a major trend shaping the cephalexin market. Bacterial infections account for an estimated 7.7 million deaths annually-roughly one in eight globally-making them the second leading cause of mortality. Alarmingly, nearly 5 million of these deaths are attributed to antibiotic-resistant strains, underscoring the escalating public health challenge posed by antimicrobial resistance.

Cephalexin continues to be widely used in the treatment of common infections such as respiratory tract infections, skin and soft tissue infections, otitis media, and urinary tract infections. The increasing frequency of such infections-driven by urbanization, climate change, poor hygiene, and increased exposure to bacterial pathogens-has sustained the demand for this well-established antibiotic.

Moreover, heightened susceptibility to both community-acquired and hospital-acquired infections, particularly in densely populated regions and developing countries, has reinforced cephalexin's role in clinical practice. Its proven effectiveness, safety profile, and cost-efficiency make it a dependable first-line option across various healthcare settings.

Key Market Players

  • Aurobindo Pharma Limited
  • Lupin Limited
  • Dykes & Dunes Enterprises Pvt. Ltd
  • Excel Pharma Chem
  • Zhejiang Anglikang Pharmaceutical Co., Ltd.,
  • Centrient Pharmaceuticals (Zibo) Co., Ltd
  • Hubei widely chemical technology Co., Ltd
  • Zhejiang Zhebang Pharmaceutical Co., Ltd
  • Akums Drugs and Pharmaceuticals Ltd.
  • Xi'an Harmonious Natural Biotechnology Co., Ltd

Report Scope

In this report, the Global Cephalexin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cephalexin Market, By Sales Channel:

  • Direct
  • Indirect

Cephalexin Market, By End Use:

  • Urinary Tract Infection
  • Respiratory Infection
  • Otitis Media
  • Bone Infection
  • Others

Cephalexin Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cephalexin Market.

Available Customizations:

Global Cephalexin Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Cephalexin Market

5. Global Cephalexin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Urinary Tract Infection, Respiratory Infection, Otitis Media, Bone Infection, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Cephalexin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cephalexin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Cephalexin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Cephalexin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Cephalexin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Cephalexin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Cephalexin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Cephalexin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Cephalexin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Cephalexin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Cephalexin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cephalexin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Cephalexin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Cephalexin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Cephalexin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Cephalexin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Cephalexin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cephalexin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Cephalexin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Cephalexin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Cephalexin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cephalexin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Cephalexin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Cephalexin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cephalexin Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Aurobindo Pharma Limited
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Lupin Limited
  • 15.3. Dykes & Dunes Enterprises Pvt. Ltd
  • 15.4. Excel Pharma Chem
  • 15.5. Zhejiang Anglikang Pharmaceutical Co., Ltd.,
  • 15.6. Centrient Pharmaceuticals (Zibo) Co., Ltd
  • 15.7. Hubei widely chemical technology Co., Ltd
  • 15.8. Zhejiang Zhebang Pharmaceutical Co., Ltd
  • 15.9. Akums Drugs and Pharmaceuticals Ltd.
  • 15.10. Xi'an Harmonious Natural Biotechnology Co., Ltd

16. Strategic Recommendations

17. About Us & Disclaimer